In a phase 3 trial, Optune Pax plus gem/nab-pac significantly improved median overall survival to 16.2 months vs 14.2 months with chemotherapy alone. The Food and Drug Administration (FDA) has ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results